May be used as a marker of severe combined immunodeficiency (SCID); lack of adenosine deaminase (ADA) allows deoxyadenosine to accumulate and kill lymphocytes.
Sun, Tue, Thu
New York DOH Approval Status
Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).
Do not freeze. Transport 1 mL whole blood.
Ambient: 15 days; Refrigerated: 15 days; Frozen: Unacceptable
Effective August 20, 2012
400-900 mU/g Hb
Adenosine Deaminase (ADA) deficiency is an autosomal recessive disorder of purine metabolism primarily affecting lymphocyte development, viability, and function. Affected individuals have less than 1 percent of normal ADA catalytic activity in red cell hemolysates. ADA deficiency is the cause of 20-30 percent of SCID cases. If the patient has been recently transfused, ADA deficiency may be masked; interpret results with caution. Heterozygotes cannot be identified by this test.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0083001||Adenosine Deaminase RBC||47549-1|